February 2018 ARTICLE LIST >>
PharmaTutor (February - 2018)
ISSN: 2347 - 7881
(Volume 6, Issue 2)
Received On: 04/11/2017; Accepted On: 16/11/2017; Published On: 01/02/2018
AUTHORS:
Priyatama V. Powar
Pharmaceutics Department
Dr. D. Y. Patil College of Pharmacy,
Akurdi, Pune
priyatama.powar@gmail.com
ABSTRACT:
Urinary Tract Infections are common health problems in clinical practice in all age groups both male and female cause by bacteria that affects urinary system. Occurrence and frequency of Urinary Tract Infection is higher in female as compare to male.
How to cite this article: Powar PV; Spermicidal Condom and Risk of Urinary Tract Infection; PharmaTutor; 2018; 6(2); 6-8; http://dx.doi.org/10.29161/PT.v6.i2.2018.6
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12: 413-420.
2. Sunil, P., Maru, O., Chan, M. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. Int J Pharm. 2005; 301(1-2): 209-216.
3. Sharma, A., Sharma, U.S. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997; 154: 123-140.
4. Gregoriadis, G. Liposomes, In Gregoriadis, G., (Ed.), Drug Carriers in Biology and Medicine. Academic Press, New York. 1979; Ch. 14. Page 287- 341.
5. Albertsson, A.C., Donaruma, L.G., Vogl, O. Synthetic polymers as drugs, In Tirrell, D.A., Donaruma, L.G., Turek, A.B., (Eds.), Macromolecules as drugs and drug as carriers for biologically active material. Ann NY Acad Sci. 1985; 446: 105-115.
6. Donaruma, L.G., Warner, R.J. Some biologically active (thiosemicarbazides). In Tirrell, D.A., Donaruma, L.G. and Turek, A.B. (Eds.), Macromolecules as drugs and drug as carriers for biologically active materials. Ann NY Acad Sci. 1985; 446: 116-133.
7. Abra, R.M., Hunt, C.A. Liposome disposition in vivo. III. Dose and vesicle size effects, Biochim Biophys Acta. 1981; 666: 493-503.
8. Tirrell, D.A., Heath, T.D., Colley, C.M., Ryman, B.E. New aspects of liposomes, Biochim Biophys Acta. 1976; 457: 259.
9. Sahoo SK, Labhasetwar V: Nanotech approaches to drug delivery and imaging. DDT 2003, 8:24.
10. Gabizon A, Goren D, Cohen R, Barenholz Y: Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998, 53:275–279.
11. Allen TM: Liposomes. Opportunities in drug delivery. Drugs 1997, 54(Suppl 4):8–14.
12. Chrai SS, Murari R, Imran A: Liposomes: a review. Bio Pharm 2001,14(11):10–14.
13. Andreas W, Karola VU: Liposome technology for industrial purposes. J Drug Delivery 2011, 2011:9.
14. Atrooz OM: Effects of alkylresorcinolic lipids obtained from acetonic extract of Jordanian wheat grains on liposome properties. Int J Biol Chem 2011, 5(5):314–321.
15. Benech RO, Kheadr EE, Laridi R, Lacroix C, Fliss I: Inhibition of Listeria innocua in cheddar cheese by addition of nisin Z in liposomes or by in situ production in mixed culture. Applied Environ Microbiol 2002, 68:3683–3690.
16. Shehata T, Ogawara K, Higaki K, Kimura T: Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. Int J Pharm 2008, 359:272–279.
17. Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR: Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta 2007, 1768:1121–1127.
.png)
